戊二醛处理同种异体心包在先天性心脏病手术中的长期结果
该研究回顾性分析了单中心2006至2016年134例先天性心脏病患者植入276片戊二醛处理冷冻保存同种异体心包(CPH)的长期结果。中位随访5.29年,无CPH相关死亡,10年免于补片相关再手术和导管干预率分别为88.5%和86.9%,总体无补片失败生存率5年和10年分别为85.8%和79.0%。结论认为CPH补片有效且耐久,再干预率低。
要点
- CPH补片在先天性心脏病手术中表现出良好的长期耐久性,再干预率低。
- 10年免于补片相关再手术率为88.5%,免于导管干预率为86.9%。
- 无死亡与CPH补片相关,总体无补片失败生存率10年为79.0%。
核心结论
- CPH补片用于先天性心脏病手术矫正有效且耐久,再干预率低,结果与其他类似使用的补片早中期结果相当。
研究设计与样本
- 单中心回顾性研究,纳入2006至2016年接受CPH植入的134例连续患者,共276片补片,分析基线特征、诊断、手术特征及术后导管和再手术报告。
主要发现
- 补片植入中位年龄1.47岁(范围1天至31.6岁),补片使用部位:肺动脉修复124片、主动脉修复57片、间隔修复49片、其他部位43片。
- 中位随访5.29年,9例死亡(6.7%),无一与CPH相关;12例(8.96%)再手术,18例(13.4%)在CPH植入部位接受导管干预。
- 10年免于补片相关再手术率为88.5%,免于导管干预率为86.9%;总体无补片失败生存率5年和10年分别为85.8%和79.0%。
临床怎么用
- CPH补片可作为先天性心脏病手术中修复肺动脉、主动脉和间隔等部位的耐久选择,再干预率低。
局限性
- 回顾性单中心设计,样本量有限,随访时间中位5.29年,可能影响长期结论的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study reports the long-term outcomes using glutaraldehyde-treated cryopreserved homograft pericardium (CPH) in neonates, infants, children, and young adults undergoing congenital cardiac surgery. METHODS: A retrospective review was performed of all patients at a single institution (Rady Children's Hospital, San Diego, CA) who had undergone surgical implantation with CPH between 2006 and 2016. The study identified 134 consecutive patients who underwent implantation of a total of 276 patches. The baseline demographic characteristics, primary cardiac diagnosis, surgical characteristics, operative reports, and postoperative catheterization and reoperation reports were analyzed. The use of CPH was categorized by specific anatomic insertion site. RESULTS: The median age at patch implantation was 1.47 years (range, 1 day to 31.6 years). The numbers and locations of patch use were 124 for pulmonary arterial repair, 57 for repair of the aorta, 49 for septal repair, and 43 at other sites. At a median follow-up of 5.29 years, 9 patients had died (6.7%), but none of those deaths were related to CPH. Twelve patients (8.96%) underwent reoperations, and 18 patients (13.4%) underwent catheter interventions at sites of CPH implantation. The 10-year freedom from patch-induced reoperation and catheter intervention rates were 88.5% and 86.9%, respectively. Overall patch failure-free survival was 85.8% and 79.0% at 5 and 10 years, respectively. CONCLUSIONS: The use of CPH patch in the surgical correction of congenital heart disease is effective and durable, as evidenced by the low reintervention rates. These results are comparable to the early and midterm outcomes of other similarly used surgical patches.
引用
- Gluck TM, Lamberti JJ, El-Said H, et al. Long-term Results Using Glutaraldehyde-treated Homograft Pericardium in Congenital Heart Surgery. Ann Thorac Surg. 2020. PMID: 33290739. doi:10.1016/j.athoracsur.2020.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。